New York State Teachers Retirement System Has $1.48 Million Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

New York State Teachers Retirement System boosted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 183.2% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,949 shares of the company's stock after purchasing an additional 14,200 shares during the quarter. New York State Teachers Retirement System owned approximately 0.06% of TransMedics Group worth $1,477,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Braidwell LP bought a new stake in shares of TransMedics Group in the 4th quarter valued at approximately $57,493,000. Norges Bank acquired a new position in shares of TransMedics Group in the 4th quarter valued at about $22,861,000. Mackenzie Financial Corp grew its position in shares of TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after buying an additional 349,403 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in TransMedics Group by 1,565.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock worth $16,820,000 after acquiring an additional 253,624 shares during the period. Finally, Emerald Advisers LLC raised its stake in TransMedics Group by 146.3% during the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock worth $23,176,000 after acquiring an additional 220,804 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TMDX shares. Oppenheimer boosted their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Piper Sandler reiterated an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, TransMedics Group presently has an average rating of "Moderate Buy" and a consensus target price of $127.33.

TransMedics Group Price Performance

Shares of TMDX traded down $1.63 during trading hours on Thursday, hitting $124.78. 650,870 shares of the company were exchanged, compared to its average volume of 1,366,268. The company has a debt-to-equity ratio of 1.92, a current ratio of 9.10 and a quick ratio of 8.32. The company has a market capitalization of $4.22 billion, a PE ratio of 91.75 and a beta of 2.06. The firm has a fifty day simple moving average of $124.35 and a 200-day simple moving average of $89.70. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. TransMedics Group's revenue for the quarter was up 48.2% on a year-over-year basis. During the same quarter last year, the company posted $0.35 EPS. As a group, sell-side analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Weill sold 732 shares of TransMedics Group stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director owned 12,134 shares in the company, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,418 shares of company stock valued at $1,512,613 over the last ninety days. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.